Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

Richard Champlin, Marcos de Lima, Partow Kebriaei, Gabriela Rondon, Tobi Fisher, Elias Jabbour, Jorge E. Cortés, Hagop Kantarjian, Paolo Anderlini, Amin Alousi, Chitra Hosing, Elizabeth Shpall, Uday Popat, Muzaffar Qazilbash, Borje Andersson, Sergio Giralt

Research output: Contribution to journalReview article

Abstract

Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.

Original languageEnglish (US)
Pages (from-to)S261-265
JournalClinical lymphoma & myeloma
Volume9 Suppl 3
StatePublished - 2009
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Transplantation
Imatinib Mesylate
Treatment Failure
Protein-Tyrosine Kinases
Tissue Donors
Lymphocytes
Transplants
Mortality

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Champlin, R., de Lima, M., Kebriaei, P., Rondon, G., Fisher, T., Jabbour, E., ... Giralt, S. (2009). Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clinical lymphoma & myeloma, 9 Suppl 3, S261-265.

Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. / Champlin, Richard; de Lima, Marcos; Kebriaei, Partow; Rondon, Gabriela; Fisher, Tobi; Jabbour, Elias; Cortés, Jorge E.; Kantarjian, Hagop; Anderlini, Paolo; Alousi, Amin; Hosing, Chitra; Shpall, Elizabeth; Popat, Uday; Qazilbash, Muzaffar; Andersson, Borje; Giralt, Sergio.

In: Clinical lymphoma & myeloma, Vol. 9 Suppl 3, 2009, p. S261-265.

Research output: Contribution to journalReview article

Champlin, R, de Lima, M, Kebriaei, P, Rondon, G, Fisher, T, Jabbour, E, Cortés, JE, Kantarjian, H, Anderlini, P, Alousi, A, Hosing, C, Shpall, E, Popat, U, Qazilbash, M, Andersson, B & Giralt, S 2009, 'Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.', Clinical lymphoma & myeloma, vol. 9 Suppl 3, pp. S261-265.
Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E et al. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clinical lymphoma & myeloma. 2009;9 Suppl 3:S261-265.
Champlin, Richard ; de Lima, Marcos ; Kebriaei, Partow ; Rondon, Gabriela ; Fisher, Tobi ; Jabbour, Elias ; Cortés, Jorge E. ; Kantarjian, Hagop ; Anderlini, Paolo ; Alousi, Amin ; Hosing, Chitra ; Shpall, Elizabeth ; Popat, Uday ; Qazilbash, Muzaffar ; Andersson, Borje ; Giralt, Sergio. / Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. In: Clinical lymphoma & myeloma. 2009 ; Vol. 9 Suppl 3. pp. S261-265.
@article{8e327535b9a842ea833740dd26da6c08,
title = "Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.",
abstract = "Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.",
author = "Richard Champlin and {de Lima}, Marcos and Partow Kebriaei and Gabriela Rondon and Tobi Fisher and Elias Jabbour and Cort{\'e}s, {Jorge E.} and Hagop Kantarjian and Paolo Anderlini and Amin Alousi and Chitra Hosing and Elizabeth Shpall and Uday Popat and Muzaffar Qazilbash and Borje Andersson and Sergio Giralt",
year = "2009",
language = "English (US)",
volume = "9 Suppl 3",
pages = "S261--265",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

AU - Champlin, Richard

AU - de Lima, Marcos

AU - Kebriaei, Partow

AU - Rondon, Gabriela

AU - Fisher, Tobi

AU - Jabbour, Elias

AU - Cortés, Jorge E.

AU - Kantarjian, Hagop

AU - Anderlini, Paolo

AU - Alousi, Amin

AU - Hosing, Chitra

AU - Shpall, Elizabeth

AU - Popat, Uday

AU - Qazilbash, Muzaffar

AU - Andersson, Borje

AU - Giralt, Sergio

PY - 2009

Y1 - 2009

N2 - Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.

AB - Allogeneic stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The success of imatinib has changed treatment recommendations, and allogeneic transplants are now reserved for imatinib treatment failures. Previous imatinib treatment does not compromise the results of ASCT, but patients with overt transformed disease have poor results. It is unclear whether patients whose disease is considered to have failed imatinib should be referred immediately for ASCT or receive treatment with a second-generation tyrosine kinase inhibitors (TKI). Patients whose disease fails 2 TKIs should receive ASCT if possible. Nonmyeloablative preparative regimens reduce the toxicity and treatment-related mortality associated with the transplantation procedure and allow transplantations to be performed in older and medically infirm patients. This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions.

UR - http://www.scopus.com/inward/record.url?scp=74049104918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049104918&partnerID=8YFLogxK

M3 - Review article

C2 - 19778850

AN - SCOPUS:74049104918

VL - 9 Suppl 3

SP - S261-265

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

ER -